Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C25H35NO5.ClH |
| Molecular Weight | 466.01 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN(CCCCOC(=O)C1=CC(OC)=C(OC)C=C1)C(C)CC2=CC=C(OC)C=C2
InChI
InChIKey=PLGQWYOULXPJRE-UHFFFAOYSA-N
InChI=1S/C25H35NO5.ClH/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5;/h9-14,18-19H,6-8,15-17H2,1-5H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C25H35NO5 |
| Molecular Weight | 429.5491 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con744437.pdf | https://www.ncbi.nlm.nih.gov/pubmed/20128021
Curator's Comment: description was created based on several sources, including:
http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con744437.pdf | https://www.ncbi.nlm.nih.gov/pubmed/20128021
Mebeverine is an antispasmodic with a direct action on the smooth muscle of the gastrointestinal tract. The exact mechanism of action is not known, but multiple mechanisms, such as a decrease in ion channel permeabilities, blockade of noradrenaline reuptake, a local anesthetic effects, as well as weak anti-muscarinic and phosphodiesterase inhibitory effect might contribute to the local effects of Mebeverine. This medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis. Most people will not have problems with Mebeverine, but some may get some side effects, such as: difficulty in breathing, swelling of face, neck, tongue or throat, skin rash, red itchy skin.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Alpha-1 adrenergic receptor (guinea pig) |
|||
Target ID: Muscarinic acetylcholine receptors (guinea pig) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Colofac Approved UseColofac is used to treat symptoms of irritable bowel syndrome and similar problems. Launch Date1978 |
|||
| Palliative | Colofac Approved UseThis medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis. Launch Date1978 |
|||
| Palliative | Colofac Approved UseThis medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis Launch Date1978 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Duspatalin in functional disorders of the Oddi's sphincter in patients subjected cholecystectomy]. | 2002 |
|
| Treatment patterns and health care costs of mebeverine-treated IBS patients: a case-control study. | 2004 Nov |
|
| Rapid accurate mass desorption electrospray ionisation tandem mass spectrometry of pharmaceutical samples. | 2005 |
|
| A new RP-HPLC method for analysis of mebeverine hydrochloride in raw materials and tablets. | 2005 Apr |
|
| [Mebeverine for complex treatment of opisthorchiasis]. | 2006 |
|
| Investigative implications of the instability and metabolism of mebeverine. | 2006 Mar |
|
| "My patients are the sickest". | 2006 May |
|
| Mebeverine influences sodium ion transport in the distal colon. | 2006 Sep-Oct |
|
| Colon-specific drug delivery for mebeverine hydrochloride. | 2007 Dec |
|
| Development of in situ ion selective sensors for dissolution. | 2007 Jan 2 |
|
| Improving the detection limits of antispasmodic drugs electrodes by using modified membrane sensors with inner solid contact. | 2007 May 9 |
|
| [Efficacy of duspatalin in the treatment and prophylaxis of postcholecystectomic syndrome]. | 2008 |
|
| Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome. | 2008 Apr |
|
| Spectrophotometric determination of benzydamine HCl, levamisole HCl and mebeverine HCl through ion-pair complex formation with methyl orange. | 2008 Mar |
|
| Drug use in children: cohort study in three European countries. | 2008 Nov 24 |
|
| Development of membrane selective electrode for determination of the antipsychotic sulpiride in pharmaceuticals and urine. | 2009 |
|
| Validated LC-MS/MS method for determination of Alverine and one of its hydroxy metabolites in human plasma along with its application to a bioequivalence study. | 2009 Jan 15 |
|
| The four killers of Meckel's diverticulum. | 2009 May |
|
| [A method for non-medicamentous treatment of irritated bowel syndrome]. | 2009 May-Jun |
|
| Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
| Colloids as a sink for certain pharmaceuticals in the aquatic environment. | 2010 May |
|
| Development and validation of stability indicating HPLC and HPTLC methods for determination of sulpiride and mebeverine hydrochloride in combination. | 2010 Sep |
|
| Autoimmune hepatitis triggered by nitrofurantoin: a case series. | 2010 Sep 23 |
|
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Patents
Sample Use Guides
One tablet (135 mg) three times a day. This may be gradually reduced after a few weeks when the desired effect has been obtained. The tablets are best taken 20 minutes before meals.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:14:12 GMT 2023
by
admin
on
Fri Dec 15 15:14:12 GMT 2023
|
| Record UNII |
15VZ5AL4JN
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C66880
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C73596
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | |||
|
C005096
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | |||
|
235827
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | RxNorm | ||
|
220-400-0
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | |||
|
2753-45-9
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | |||
|
m7108
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | Merck Index | ||
|
15VZ5AL4JN
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | |||
|
SUB03102MIG
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | |||
|
CHEMBL282121
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | |||
|
17683
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | |||
|
DTXSID1045372
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | |||
|
169101
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY | |||
|
100000086181
Created by
admin on Fri Dec 15 15:14:12 GMT 2023 , Edited by admin on Fri Dec 15 15:14:12 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |